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Highlights 
● Mice fed a diet with vitamin D2 only from weaning showed lower levels of total serum 
25OHD than mice fed a vitamin D3 diet at 8 weeks of age  
● Mice fed vitamin D2 only showed higher levels of free serum 25OHD than vitamin D3 mice  
● Mice fed vitamin D2 or vitamin D3 diets showed similar severity of colitis induced by 
dextran sodium sulphate 
● Free 25OHD may be more important than total 25OHD for anti-inflammatory responses    
 
 
 
Abstract 
Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease have been 
linked to vitamin D-deficiency. Using a dextran sodium sulphate (DSS)-induced model of IBD 
we have shown previously that mice raised on vitamin D-deficient diets from weaning have 
lower serum 25-hydroxyvitamin D (25OHD) levels and develop more severe colitis compared 
to vitamin D-sufficient counterparts. We have also shown in vitro that immune responses to 
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25OHD may depend on ‘free’ rather than total serum concentrations of 25OHD. To 
investigate the possible effects of free versus total 25OHD on anti-inflammatory immune 
responses in vivo we have studied DSS-induced colitis in wild type C57BL/6 mice raised 
from weaning on diets containing vitamin D2 (D2) or vitamin D3 (D3) only (both 1000 IU/kg 
feed). 25OHD2 has lower binding affinity for the vitamin D binding protein than 25OHD3 
which results in higher levels of free 25OHD2 relative to free 25OHD3 in mice raised on a 
D2-only diet. Total serum 25OHD concentrations, measured by liquid chromatography-
tandem mass spectrometry (LC-MS/MS), showed that D2 mice had significantly lower levels 
of 25OHD than D3 mice (6.85±2.61 nmol/L vs. 49.16±13.8 nmol/L for D2 and D3 
respectively). Despite this, direct ELISA measurement showed no difference in free serum 
25OHD levels between D2 and D3 mice (13.62±2.26 pmol/L vs. 14.11±2.24 pmol/L for D2 
and D3 respectively). Analysis of DSS-induced colitis also showed no difference in weight 
loss or disease progression between D2 and D3 mice. These data indicate that despite D2-
fed mice being vitamin D-deficient based on serum total 25OHD concentrations, these mice 
showed no evidence of increased inflammatory colitis disease relative to vitamin D-sufficient 
D3 mice. We therefore propose that free, rather than total serum 25OHD, may be a better 
marker of immune responses to vitamin D in vivo.  
 
 
 
 
1. Introduction 
The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D), is a potent 
immunomodulator that stimulates both innate antimicrobial [1-3] and adaptive anti-
inflammatory [4, 5] responses. These immune regulatory effects appear to be mediated via 
intracrine conversion of pro-hormone 25-hydroxyvitamin D (25OHD) to 1,25(OH)2D by 
antigen presenting cells (APC) such as macrophages and dendritic cells (DC) [6, 7]. Thus, 
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the delivery of 25OHD to target APC is a critical component of the mechanism by which 
vitamin D is able to influence immune function. As with the majority of steroid hormones, 
vitamin D metabolites are chaperoned in the circulation by serum globulins, of which vitamin 
D binding protein (DBP) accounts for 85-90% of bound 25OHD and albumin 10-15%; hence, 
less than 1% remains in the unbound or ‘free’ state [8]. Endocrine activation of vitamin D by 
the kidney utilises bound 25OHD for proximal tubule reabsorption via megalin/cubilin-
mediated receptor endocytosis [9]. However, many other target cells do not express the 
megalin/tubulin complex and are thus only able to access 25OHD and other vitamin D 
metabolites via non-facilitated mechanisms. Prominent amongst these is the ‘free-hormone 
hypothesis’, which proposes that only unbound steroid hormones are able to enter target 
cells [10, 11]. In previous studies in vitro using megalin/tubulin-negative monocytes, we have 
shown that DBP impairs antibacterial responses to 25OHD and 1,25(OH)2D [12, 13] 
suggesting that free 25OHD may be particularly important for regulation of immune 
responses. The aim of the current study was to assess the importance of free versus total 
serum 25OHD as a determinant of anti-inflammatory immune function in vivo.   
 
The amount of free 25OHD is dependent on serum concentrations of DBP and albumin, and 
the DBP binding affinity of 25OHD [13, 14]. Knockout of the gene for DBP (Gc) in mice 
provides only a limited perspective on the relationship between total and free 25D, because 
total serum levels of vitamin D metabolites are substantially reduced in both Gc+/- and Gc-/- 
mice [15]. In recent studies we have shown that it is possible to disengage total and free 
serum  25OHD by exploiting the greater DBP binding affinity of 25OHD3 relative to its 
vitamer equivalent 25OHD2 [16-18]. Mice raised on diets containing exclusively vitamin D2 
showed increased serum concentrations of free 25OHD relative to mice raised on vitamin D3 
only despite having similar levels of total 25OHD2 or 25OHD3 respectively [19]. The 
increased free 25OHD in vitamin D2 mice was associated with significant changes in bone 
and immune cell function, suggesting that total serum 25OHD measurements alone did not 
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reflect the biological potential of this vitamin D metabolite [19]. To determine the relative 
impact of total versus free 25OHD on immune responses in vivo we carried out further 
studies using mice raised on D2 and D3 diets and then treated to induce inflammatory 
disease. The over-arching objective in this case was to determine whether free 25OHD 
rather than total 25OHD is a better determinant of the anti-inflammatory activity of 25OHD.   
 
2. Materials and Methods 
2.1 Animals 
Male C57BL/6 mice (Charles River UK) aged three weeks were fed diets that contained 
either vitamin D2 (D2, n=16) or vitamin D3 (D3, n=16), at concentrations of 1000 IU/kg 
(Research Diets Inc. New Brunswick, NJ 08901 USA), for five weeks. Mice were housed four 
per cage, had ad libitum access to food and water throughout the study and were maintained 
on a 12:12 hour light-dark cycle at a temperature of 21-22 °C. All procedures were in 
accordance with the Animals (Scientific Procedures) Act 1986, regulated by the UK Home 
Office and were conducted at the Biomedical Services Unit, University of Birmingham, UK. 
 
2.2 Induction of colitis in mice using dextran sodium sulphate 
At eight weeks of age, 2.5% dextran sodium sulphate (DSS, MP pharmaceuticals, Santa 
Ana, USA) was administered to eight mice per group via drinking water for seven days, 
leaving the remaining eight per group as water treated controls. The treatment period was 
followed by a three day resolution phase, whereby DSS was withdrawn from drinking water 
to allow mice a period of recovery.   
 
2.3 Mouse health Score  
To monitor health during experiments, mice were scored daily upon starting DSS treatment. 
By calculating percentage weight loss and assigning faecal consistency and anal bleeding 
scores, colitis disease progression could be quantified. The scoring system used was as 
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follows. A calculated weight loss of less than 1% was scored as 0, a 1-5% loss as 1, a 5-
10% reduction was given a 2, a 10-20% weight loss as 3, and if a mouse lost more than 20% 
it would be euthanised as this indicated an end point. Faecal consistency was scored thus; 
well-formed pellets were scored 0, pasty stools were given a 2, and watery stools scored as 
4. Finally, no anal bleeding was scored as 0, if a spot of blood was observed in the anus a 
score of 2 was assigned, whilst gross bleeding was given a score of 4. Scores were added 
together and mice with combined scores greater than 9 were euthanised (Table 1).   
 Score 0 1 2 3 4 
Weight loss None 1-5% 5-10% 10-20% ≥20% 
Stool consistency Well formed  - Pasty  - Watery 
Anal bleeding None  - Spot  - Gross 
 
Table 1. Disease scoring of a mouse model of colitis. Mice were monitored daily for 
weight loss, stool consistency and anal bleeding. These parameters were assigned scores 
dependent on presence and/or severity. Any mouse with a combined health score of nine or 
greater was humanely sacrificed; as were mice with a weight loss of ≥20%.   
 
2.4 Tissue collection 
At the conclusion of the study, cardiac bleeds were performed under terminal anesthesia 
and bloods collected into micro centrifuge tubes, left at room temperature to allow 
coagulation, were centrifuged and resultant sera stored at -80 °C. Tissues were excised, 
dissected and promptly snap-frozen in LN2 and fixed in 4% formaldehyde for later analyses.  
 
2.5 Quantification of serum 25OHD 
Both total and free 25OHD were quantified from collected mouse sera. Free 25OHD analysis 
was performed using enzyme-linked immunosorbent assay (ELISA) according to the 
manufacturer’s instructions (Diasource, cat no: KAPF1991). This assay has 77% cross-
reactivity with 25D2. Total serum 25OHD was analysed using Liquid Chromatography-
Tandem Mass Spectrometry (LC-MS/MS) as described previously, with slight modifications 
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[20, 21]. In brief, samples were prepared for analysis by protein precipitation and supported 
liquid-liquid extraction (SLE). Samples were derivatized with 4-(2-(6,7-dimethoxy-4-methyl-3-
oxo-3,4-dihydroquinoxalinyl)ethyl)-1,2,4-triazoline-3,5-dione (DMEQ-TAD) as previously 
described [22]. Analysis of serum was performed on a Waters ACQUITY ultra performance 
liquid chromatography (UPLC) coupled to a Waters Xevo TQ-XS mass spectrometer. The 
LC-MS/MS method has been validated on US Food and Drug Administration guidelines for 
analysis of these metabolites as previously described (32). 
 
2.6 Histological analysis of colon 
Excised colons were washed with PBS before being coiled, placed into processing cassettes 
and fixed in 10% neutral-buffered formalin (4% formaldehyde) prior to embedding in paraffin 
wax. Sections were cut to 5 µm and haematoxylin and eosin staining performed using 
standard procedures. Briefly, sections were de-waxed and re-hydrated through serial 
dilutions of industrial methylated spirits, stained in haematoxylin and washed in Scott’s 
water. This was followed by staining in eosin, washing in water and dehydration through 
serial dilutions of industrial methylated spirits before clearing and mounting. Sections were 
viewed using light microscopy and images taken using a Leica imaging system.  
 
Histological scoring of haematoxylin and eosin stained colonic tissue sections was 
performed blinded as described previously [23] for: 1) inflammatory cell infiltration. The 
presence of occasional inflammatory cells in the lamina propria=0; Increased numbers of 
inflammatory cells in the lamina propria=1; Confluence of inflammatory cells, extending into 
the submucosa=2; Transmural extension of the infiltrate=3. 2) ulceration, and tissue 
damage.  No mucosal damage was scored=0; Discrete lymphoepithelial lesions=1; Surface 
mucosal erosion or focal ulceration=2; Extensive mucosal damage and extension into 
deeper structures of the bowel wall=3. Values for n=4 fields of vision from each of the mouse 
colons for vitamin D2 and vitamin D3 treated mice were obtained. Values were totalled and 
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divided by the total number of fields of vision. The combined histological score ranged from 0 
(no changes) to 6 (extensive cell infiltration and tissue damage). 
 
2.7 Statistics 
Data for body weight changes and scoring were compared using student’s t-test. Total and 
free 25OHD values were compared using ANOVA, with Tukey's multiple comparisons test; 
with significance assigned where P<0.05. 
 
3. Results 
3.1 Vitamin D2 is associated with deficient levels of total but not free serum 25OHD  
At the completion of the study, control (water only) D3-fed mice had higher serum 
concentrations of 25OHD3 (42.61±3.40 nmol/L) than D2-fed mice (12.41±0.85 nmol/L, 
p<0.0001). DSS-treated D3-fed mice also had higher serum concentrations of 25OHD3 
(49.16±5.21 nmol/L) than D2-fed mice 
(6.85±0.92 nmol/L, P<0.0001) mice 
(Fig. 1A).  
Figure 1. Total and free 25OHD in 
vitamin D2 and vitamin D3 fed mice. 
In DSS- or water-treated D2 and D3 
mice: (A) Total serum 25OHD2 and 
25OHD3 determined by LC-MS/MS (B) 
Free serum 25OHD determined by 
ELISA (C) Ratios of free to total 25OHD. 
Data are shown as mean values ± SEM; 
statistical analyses performed using 
ANOVA; **P<0.01, ****P<0.0001; n=8 
mice/treatment group. 
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In contrast to the total 25OHD data, analysis of free serum 25OHD by ELISA showed that in 
DSS treated mice, levels were similar in both groups (13.62±0.80 pmol/L vs. 14.11±0.85 
pmol/L for D2/D3 respectively). However, in water control mice, free 25OHD levels were 
four-fold higher in D2 mice compared to D3 mice (77.2±2.83 pmol/L vs. 18.21±1.60 pmol/L, 
P<0.0001 for D2/D3 respectively)(Fig. 1B). The ratio of free to total 25OHD was 7.5 and 16 
times higher in D2 fed mice relative to D3 fed mice (1:430 vs. 1:3239 and 1:156 vs. 1:2472 
for DSS-treated and water controls respectively) (Fig. 1C). Additional serum metabolites 
measured for the D3 fed mice showed significantly decreased levels of 1,25(OH)2D3 
(157.50±19.20 pmol/L vs. 239.57±28.82 pmol/L, P<0.05), 3-Epi-25OHD3 (1.17±0.26 nmol/L 
vs. 4.78±0.61 nmol/L, p<0.001) and 24,25(OH)2D3 (32.83±4.69 nmol/L vs. 92.13±12.03 
nmol/L, P<0.01) in DSS-treated mice versus water controls.  
 
3.2 Effects of D2 and D3 on DSS-induced colitis. 
Daily weighing of mice at the commencement of DSS treatment showed there was no 
significant difference between body weight changes at the conclusion of the study between 
D2 vs. D3 fed mice cohorts, although D3 fed mice did gain significantly more weight in the 
first four days than their D2 fed counterparts (Fig. 2 and Fig 3A). Moreover, both D2 and D3 
groups lost weight at similar rates between days 5 and 7 of DSS treatment: -0.3/-0.7%, -4.5/-
4.7%, -9.5/-10.7% on days 5, 6 and 7 for D2/D3 treated mice respectively. In contrast to 
DSS-treated mice, control water-only mice showed steady increases in body weight 
throughout the 10 day treatment period with D2 mice showing statistically higher weight gain 
on days 6 and 8 (Fig. 3B).           
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Figure 2. Individual weight 
changes for DSS-treated D2 and 
D3 mice. % change in body weight 
for individual mice during (day 0-7) 
and after (day 8-10) treatment with 
DSS (2.5% in water). A. Individual 
D2 mice (D2M1-D2M8). B Individual 
D3 mice (D3M1-D3M8). 
 
 
 
 
 
Mouse health and colitis disease progression was also monitored by observing faecal 
consistency and the presence or extent of anal bleeding. D2 fed mice appeared to show 
earlier effects of DSS treatment, manifesting in aberrant stool formation approximately a day 
earlier than in D3 fed mice (Fig. 3C). Consequently, D2 mice reached peak colitis disease 
severity at day 7 and D3 mice at day 8 (scores of 6±0.5 and 3.57±0.62, P<0.01 for D2/D3 
respectively) of DSS treatment. D3 fed mice also appeared to recover more quickly than D2 
fed mice (scores of 3.57±0.37 and 2.29±0.29, P<0.05) after removal of DSS treatment. H&E 
staining of paraffin embedded colonic sections for D2 and D3 fed mice showed variable, but 
comparable pathology of the colon, with similar levels of inflammatory cell tissue invasion 
and mucosal ulceration damage for D2 and D3 mice (Fig. 4).         AC
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Figure 3. Effect of DSS on body 
weight and colitis disease score 
in D2 and D3 mice.  A. % change 
in body weight for D2 and D3 mice 
during (day 0-7) and after (day 8-10) 
treatment with DSS (2.5% in water). 
B. In water only control mice. C. 
Colitis disease scores for D2 and 
D3 mice:  during (day 0-7) and after 
(day 8-10) treatment with DSS 
(2.5% in water). Data are shown as 
mean ± SEM; statistical analyses 
performed using Student’s t-test; 
*P<0.05; n=8 mice/treatment group. 
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Figure 4. Histopathological analysis of excised and dissected colons for DSS-treated 
D2 and D3 fed mice. Colons were fixed in formalin and embedded in paraffin wax before 
being sectioned at 5 µm. A. Both D2 and D3 mice showed signs of inflammation (red 
arrows), determined by H&E staining.  B. Quantification of histological scoring for 
inflammatory infiltration (0 – 3, red arrows) combined with scoring for mucosal ulceration 
damage (0 – 3, blue arrows) in D2 and D3 fed mice exposed to DSS.  Data are mean ± SD 
for n=7 mice .  
 
 
4. Discussion 
Several lines of evidence have highlighted a role for vitamin D in anti-inflammatory 
responses in the gastrointestinal tract. Firstly, epidemiology has shown that patients with 
inflammatory bowel disease (IBD) have decreased serum levels of 25OHD [24-26]. 
Secondly, in humans, expression of the vitamin D-activating enzyme CYP27B1 has been 
detected in colonic epithelial cells [27], with CYP27B1 expression being altered in affected 
tissue from patients with Crohn’s disease [28]. Finally, in studies using various animal 
models, active 1,25(OH)2D has been shown to play a crucial role in the pathophysiology of 
AC
CE
PT
ED
 M
AN
US
CR
IPT
13 
 
 
experimental colitis [29-33]. These models include mice with knockout of the Vdr gene [29, 
31], and knockout of the Cyp27b1 gene [32], both of which showed increased severity of 
inflammatory colonic disease with different models of colitis. In previous studies we have 
also shown that wild type mice raised from weaning on a vitamin D-deficient diet with low 
serum concentrations of 25OHD are also more susceptible to experimental colitis [33]. This 
latter observation confirmed similar observations in humans with IBD [24-26], but also 
suggested that 25OHD, rather than active 1,25(OH)2D, is a key determinant of immune 
regulation. The likely mechanism for 25OHD as an attenuator of inflammatory disease is via 
intracrine or paracrine synthesis of 1,25(OH)2D from 25OHD [5]. However, an important 
additional consideration for 25OHD is that it is the vitamin D metabolite with the highest 
binding affinity for serum DBP. As such, the relationship between 25OHD and DBP may be a 
key factor in mediating both skeletal and extra-skeletal actions of vitamin D. The aim of the 
current study was to determine how DBP binding of 25OHD, and free 25OHD, impacts the 
anti-inflammatory effects of 25OHD. 
 
The first notable observation from this study is that mice fed a D2 only diet had lower 
circulating levels of 25OHD than mice fed D3, in either the water control mice or with DSS-
induced colitis. In a previous report by our group the serum levels of 25OHD in mice on D2- 
and D3-only diets were not significantly different after a similar time period (8 weeks) [19]. 
The most likely explanation for this is that the two different studies were carried out in 
different animal facilities and with wild type C57/BL6 mice from different sources. However, 
lower serum levels of 25OHD with a mouse vitamin D2 diet are consistent with previous 
analysis of non-human primates, where 2-3-fold higher serum 25OHD concentrations were 
observed with D3 diet relative to D2 [34]. Likewise, human studies have shown that D2 
supplementation resulted in lower increases in serum 25OHD levels [35]. The proposed 
explanation for this is that the lower binding affinity of 25OHD2 for DBP results in less renal 
reabsorption of 25OHD2 via megalin-mediated endocytosis in the proximal tubule. This may, 
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in turn, lead to lower levels of 1,25(OH)2D2, but unfortunately we were only able to quantify 
1,25(OH)2D3 in the LC-MS/MS assay used in this study. It was also interesting to note that 
in D2 mice the low serum 25OHD2 levels in control mice decreased still further with DSS 
treatment. By contrast there was no effect of DSS on serum 25OHD3 levels. The reason for 
this is unclear, and is unlikely to be linked to DSS-induced inflammation as both sets of mice 
showed equivalent severity of colitis.    
 
Although total 25OHD2 levels were much lower than total 25OHD3 in the two sets of mice, 
ELISA-measured free 25OHD was significantly higher in D2 control mice and no different 
from D3 in D2 DSS mice. As outlined above, this can be explained by the lower binding 
affinity of 25OHD2 for DBP relative to 25OHD3 leading to increased free 25D2, and the 
increased ratio of free/total 25OHD in D2 mice is consistent with our previous studies of D2 
versus D3 mice [19].  Interestingly, the 16-fold higher ratio of free/total 25OHD in D2 versus 
D3 water control mice, was decreased to 7.5-fold in DSS-treated mice. These data suggest 
that the equilibrium between total and free 25OHD2 may be influenced by the inflammatory 
disease itself. The explanation for this is unclear, but could involve increased circulating 
levels of DBP and/or other serum binding proteins such as albumin. These proteins were not 
measured in the current set of experiments but should be an important feature of future 
studies. It was also interesting to note that in D3 mice serum levels of 1,25(OH)2D3, 3-epi-
25OHD3 and 24,25(OH)2D3 were significantly lower in DSS-treated mice compared to 
regular water D3 controls. In previous studies of humans serum 1,25(OH)2D3 levels have 
been reported to be elevated in some patients with Crohn’s disease, but not patients with 
ulcerative colitis [28]. This was attributed to increased extra-renal synthesis of 1,25(OH)2D3 
by macrophages in disease-affected tissues, similar to granulomatous disorders such as 
sarcoidosis. However, studies of other inflammatory diseases such as rheumatoid arthritis 
an inverse correlation between disease activity and serum levels of 1,25(OH)2D3 have been 
observed [36]. One possible explanation for this is that the systemic inflammation that is 
AC
CE
PT
ED
 M
AN
US
CR
IPT
15 
 
 
characteristic of diseases such as rheumatoid arthritis acts to inhibit renal activity of the 
enzyme CYP27B1, possibly via NF-κB suppression of CYP27B1 gene promoter activity [37].  
 
The crucial observation from the current study is that although D2 mice had total serum 
25OHD levels that were seven times lower than D3 mice, they showed similar responses to 
DSS-induced colitis. In a previous DSS-induced colitis study using mice fed a D3 diet versus 
a diet with no D3 (vitamin D-deficient), we observed a similar difference in total 25OHD 
levels to that documented in the current study [23]. In the D3-deficient mice low serum 
25OHD was associated with a significant increase in colitis severity, which we were able to 
show was due to altered colonic expression of a range of different genes associated with 
immune and barrier function [23]. It is difficult to make a direct comparison between these 
two studies as vitamin D deficiency was not an objective of the D2 diet in the current study. 
Nevertheless, the current data strongly suggest that in the setting of inflammatory disease, 
quantification of total serum 25OHD may have only limited value. Instead the similar patterns 
of colitis in D2 and D3 mice would appear to be more closely linked to the similar serum 
concentrations of free 25OHD2 and 25OHD3 respectively in these mice. Although levels of 
free 25OHD are relatively small, the potential for this fraction of 25OHD to more effectively 
promote immune responses is consistent with our previous ex vivo data suggesting that free 
25OHD is the key determinant of monocyte antibacterial responses to 25OHD [12]. 
However, it is also important to recognize that the higher levels of total 25OHD in D3 mice 
may also have some benefits. Notably the onset of DSS-induced disease appeared to be 
earlier in D2 mice (see Figures 2 and 3), even though the peak weight loss and colitis 
scores were similar for D2 and D3 treatments. It is therefore possible that early events in the 
onset of colitis, such as barrier integrity [38] are influenced more by total 25OHD. 
 
Over the last 5 years there has been considerable debate concerning the relative merits of 
total versus free serum 25OHD [39-41]. It seems likely that in normal healthy individuals free 
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serum 25OHD is very closely linked to total serum 25OHD and, as such, measurement of 
free 25OHD may have no significant advantage as a marker of ‘vitamin D status’. However, 
significant variations in the ratio of free/total 25OHD have been reported in patients with 
diseases such as cirrhosis of the liver [42], suggesting that in some settings free 25OHD is a 
more accurate measure of vitamin D function. Likewise, in vitamin D-deficient patients, an 
early rise in free 25OHD following vitamin D supplementation was shown to be more strongly 
associated with changes in vitamin D biomarkers such as PTH than total 25OHD [43]. The 
extent to which variations in total and free 25OHD impact inflammatory disease is still 
unclear. In studies using elderly human subjects we were unable to determine any significant 
difference when using total or free serum 25OHD as correlates for circulating inflammatory 
cytokines [44]. However, in this case it is important to recognise that only a very limited 
selection of inflammatory markers were measured, and the cohort was an otherwise healthy 
one with no established inflammatory disease. Based on these observations, we 
hypothesise firstly that in the setting of inflammatory disease free 25OHD is a better indicator 
of the anti-inflammatory potential of vitamin D. Secondly, we propose future studies to 
investigate the potential benefits of supplementation with vitamin D2 versus vitamin D3 for 
some actions of vitamin D, notably immunomodulatory actions. As described by Bouillon et 
al. in a recent commentary [45], in this setting it may be useful to consider vitamin D2 as an 
‘analog’ of vitamin D rather than a bioequivalent vitamer.   
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